EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

APOE ε4 gene dose drives a canonical and predictable topography of amyloid deposition

Augusto J Mendes iD, Cecilia Boccalini, Federica Ribaldi, Michela Pievani, Débora Peretti, Valentina Garibotto, Andrea Chincarini, Giovanni B Frisoni, Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & Dementia · 2026-10 · 22 (10)

DOI: 10.1002/alz.71935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 29.10.2026. Verfasst von Augusto J Mendes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Apolipoprotein E4, Alzheimer Disease, Brain, Gene Dosage. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Fondation Segré, Ivan Pictet, Race Against Dementia Foundation, Fondation Child Care, Fondatio…, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Apolipoprotein E ε4 (APOE ε4) carriership is associated with higher amyloid burden in Alzheimer's disease (AD), but whether it constrains the spatial predictability of amyloid deposition at the individual level remains unknown. METHODS We analyzed voxel‐wise amyloid positron emission tomography data from 781 amyloid‐positive individuals across two independent cohorts (Alzheimer's Disease Neuroimaging Initiative and Geneva Memory Center), spanning the full clinical continuum. Individual topographic similarity to canonical AD amyloid maps and within‐group spatial homogeneity were assessed via voxel‐wise correlations and linear regression adjusted for age, sex, and global amyloid burden. RESULTS APOE ε4 carriers exhibited amyloid distributions more aligned with canonical AD topographies than non‐carriers ( p < 0.001), with a clear gene‐dose effect on within‐group spatial homogeneity: Homozygotes showed the highest inter‐subject consistency, followed by heterozygotes and non‐carriers. Effects were robust across tracers, clinical stages, and cohorts. DISCUSSION APOE ε4 gene dose constrains the spatial predictability of amyloid accumulation, informing genotype‐stratified approaches in anti‐amyloid trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein E4Alzheimer DiseaseBrainGene DosageAmyloidAmyloid beta-PeptidesHumansFemalePositron-Emission TomographyMaleAgedHeterozygoteGenotypeAged, 80 and over

Stichwörter der Autor:innen

APOE ε4Alzheimeramyloidgenetictopography

Substanzen

Apolipoprotein E4AmyloidAmyloid beta-Peptides

Autor:innen und Institutionen

  • Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
  • Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.
  • Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland.
  • CIBM Center for Biomedical Imaging, Geneva, Switzerland.

ORCID-Profile: Augusto J Mendes

Förderung

  • Swiss National Science Foundation
  • Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Fondation Segré, Ivan Pictet, Race Against Dementia Foundation, Fondation Child Care, Fondatio…
  • NIH HHS
  • Alzheimer's Disease Neuroimaging Initiative (ADNI)
  • National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
  • NIA NIH HHS
  • DOD ADNI (Department of Defense)
  • AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.…

Zitieren

APA

Mendes, A. J., Boccalini, C., Ribaldi, F., Pievani, M., Peretti, D., Garibotto, V., Chincarini, A., Frisoni, G. B., & Alzheimer's Disease Neuroimaging Initiative (2026). APOE ε4 gene dose drives a canonical and predictable topography of amyloid deposition. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71935

Vancouver

Mendes AJ, Boccalini C, Ribaldi F, Pievani M, Peretti D, Garibotto V, et al. APOE ε4 gene dose drives a canonical and predictable topography of amyloid deposition. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71935

BibTeX
@article{Mendes2026,
  author = {Mendes, Augusto J and Boccalini, Cecilia and Ribaldi, Federica and Pievani, Michela and Peretti, Débora and Garibotto, Valentina and Chincarini, Andrea and Frisoni, Giovanni B and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {APOE ε4 gene dose drives a canonical and predictable topography of amyloid deposition},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {10},
  doi = {10.1002/alz.71935}
}
Kostenlos starten →